Literature DB >> 6388833

Treatment of myeloid blastic crisis of chronic myelogenous leukemia.

H D Preisler, A Raza, D Higby, J Kirshner, J Woll, J Bennett, L Winton, R Weiner, C Richman, H Golomb.   

Abstract

Patients with myeloid blastic crisis of chronic myelogenous leukemia were treated by chemotherapy or by autologous hematopoietic reconstitution after aggressive chemotherapy. Chemotherapy alone failed to produce a second chronic phase. Autologous transplantation resulted in the establishment of a second chronic phase in two of ten patients treated with a four-drug regimen, while treatment with high-dose cytarabine with or without busulfan resulted in the establishment of a second chronic phase in three of six patients and the return of normal hematopoiesis in a fourth. Consolidation chemotherapy appeared to be beneficial.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6388833

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  2 in total

1.  Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.

Authors:  L V Ramilo-Torno; V I Avramis
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

2.  Daunomycin, cytosin-arabinoside and VP-16 (DAV) for myeloid blast crisis of CML.

Authors:  B Anger; H Heimpel
Journal:  Blut       Date:  1989-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.